Berkan Karabuga

13PUBLICATIONS
124CO-AUTHORS
Molecular targetsBiomechanicsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jun 25, 2026
Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.

|Jun 23, 2026
From the stands to survival fandom, a psychosocial force in the fight against cancer.

|May 27, 2026
Prognostic Value of the Prognostic Nutritional Index in Patients with Locally Advanced Bladder Cancer Receiving Perioperative Chemotherapy: A Multicenter Real-World Study.

|May 04, 2026
Clinicopathological Predictors of Pathological Complete Response in HER2-Positive Breast Cancer Treated with Pertuzumab-Based Neoadjuvant Therapy: A Multicenter Real-World Study.

|Mar 28, 2026
Tyrosine Kinase Inhibitor Therapy in Metastatic Medullary Thyroid Carcinoma: Real-World Data from Turkish Oncology Group.

Sedat Yıldız, Hacer Demir, Talha Özüdoğru

|Mar 26, 2026
Neutropenia and G-CSF use in patients receiving FOLFOX during the COVID-19 pandemic.

Berkan Karabuğa, Hatice Gülgün Fırat, Fatih Tay

Pageof 3

Frequent Collaborators

4 joint publications

Elif Sahin

4 joint publications

Ali Kalem

3 joint publications

Öztürk Ateş

3 joint publications

Mustafa Seyyar